Form 4: Sensei Biotherapeutics Executive Acquires Stock Options

Edward van der Horst, Chief Scientific Officer of Sensei Biotherapeutics, acquired stock options for 110,000 shares on February 14, 2025.

Summary

• Edward van der Horst, the Chief Scientific Officer of Sensei Biotherapeutics, acquired stock options on February 14, 2025.
• The options grant the right to buy 110,000 shares of Sensei Biotherapeutics stock at an exercise price of $0.476 per share.
• The options vest over four years, with 25% vesting on February 14, 2026, and the remainder vesting monthly over the subsequent three years, contingent upon continuous service with the company.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of stock option grants to an executive, which is a common practice.

Industry Context

This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for executives to receive stock options as part of their compensation packages, aligning their interests with those of shareholders.

Stakeholder Impact

• The granting of stock options aligns the executive's interests with those of shareholders, potentially incentivizing them to increase company value.

Key Dates

Keywords

stock options, Sensei Biotherapeutics, Form 4, insider trading, executive compensation, SNSE, van der Horst, Chief Scientific Officer